Research of Pathogenesis and Novel Therapeutics in Arthritis
Arthritis has a high prevalence globally and includes over 100 different types, the most common of which are rheumatoid arthritis, osteoarthritis, psoriatic arthritis, and inflammatory arthritis. The exact etiology of arthritis remains unclear and no cure exists. Anti-inflammatory drugs are commonly...
| Format: | eBook |
|---|---|
| Language: | English |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2019
|
| Subjects: | |
| Online Access: | Open Access: DOAB: description of the publication Open Access: DOAB, download the publication |
| LEADER | 05159namaa2201609uu 4500 | ||
|---|---|---|---|
| 001 | doab58295 | ||
| 003 | oapen | ||
| 005 | 20210212 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 210212s2019 xx |||||o ||| 0|eng d | ||
| 020 | |a 9783038970651 | ||
| 020 | |a 9783038970668 | ||
| 020 | |a books978-3-03897-066-8 | ||
| 024 | 7 | |a 10.3390/books978-3-03897-066-8 |2 doi | |
| 040 | |a oapen |c oapen | ||
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 720 | 1 | |a Tang, Chih-Hsin |4 aut | |
| 245 | 0 | 0 | |a Research of Pathogenesis and Novel Therapeutics in Arthritis |
| 260 | |b MDPI - Multidisciplinary Digital Publishing Institute |c 2019 | ||
| 300 | |a 1 online resource (366 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |f Unrestricted online access |2 star | |
| 520 | |a Arthritis has a high prevalence globally and includes over 100 different types, the most common of which are rheumatoid arthritis, osteoarthritis, psoriatic arthritis, and inflammatory arthritis. The exact etiology of arthritis remains unclear and no cure exists. Anti-inflammatory drugs are commonly used in the treatment of arthritis but are associated with significant side effects. Novel modes of therapy and additional prognostic biomarkers are urgently needed for arthritis patients. This book summarizes and discusses the global picture of the current understanding of arthritis. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by-nc-nd/4.0/ |2 cc |u https://creativecommons.org/licenses/by-nc-nd/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine and Nursing |2 bicssc | |
| 653 | |a adalimumab | ||
| 653 | |a adipokines | ||
| 653 | |a adjuvant arthritis | ||
| 653 | |a angiogenesis | ||
| 653 | |a antagonists | ||
| 653 | |a anti-arthritis | ||
| 653 | |a antibodies | ||
| 653 | |a anticitrullinated peptide antibodies | ||
| 653 | |a antirheumatic drug | ||
| 653 | |a arthritis | ||
| 653 | |a articular cartilage | ||
| 653 | |a autoimmune | ||
| 653 | |a basic research | ||
| 653 | |a bioinformatics | ||
| 653 | |a biological | ||
| 653 | |a biomarkers | ||
| 653 | |a biosimilars | ||
| 653 | |a bisphosphonate | ||
| 653 | |a bone erosion | ||
| 653 | |a bone morphogenetic protein | ||
| 653 | |a celastrol | ||
| 653 | |a cell signaling | ||
| 653 | |a certolizumab pegol | ||
| 653 | |a chemokines | ||
| 653 | |a chondrocytes | ||
| 653 | |a clinical translation | ||
| 653 | |a clodronate | ||
| 653 | |a collagen | ||
| 653 | |a collagen-induced arthritis | ||
| 653 | |a computational modeling | ||
| 653 | |a cytokines | ||
| 653 | |a disease pathways | ||
| 653 | |a disease-modifying | ||
| 653 | |a drug delivery system | ||
| 653 | |a early osteoarthritis | ||
| 653 | |a Epstein-Barr virus | ||
| 653 | |a etanercept | ||
| 653 | |a experimental arthritis | ||
| 653 | |a fibroblast growth factor 2 | ||
| 653 | |a fraxinellone | ||
| 653 | |a gene expression | ||
| 653 | |a glycoprotein 42 | ||
| 653 | |a glycosylation | ||
| 653 | |a golimumab | ||
| 653 | |a IL-6 | ||
| 653 | |a IL1? | ||
| 653 | |a immunology | ||
| 653 | |a inflammation | ||
| 653 | |a inflammatory arthritis | ||
| 653 | |a infliximab | ||
| 653 | |a interleukin | ||
| 653 | |a MAPK | ||
| 653 | |a mesenchymal stem cells | ||
| 653 | |a messenger RNA | ||
| 653 | |a mice | ||
| 653 | |a microRNA | ||
| 653 | |a miR-199a-5p | ||
| 653 | |a miRNA | ||
| 653 | |a mitogen activated protein kinase | ||
| 653 | |a molecular pathology | ||
| 653 | |a next-generation sequencing | ||
| 653 | |a nitric oxide | ||
| 653 | |a nuclear factor kappa B | ||
| 653 | |a obesity | ||
| 653 | |a osteoarthritis | ||
| 653 | |a osteoarthritis (OA) | ||
| 653 | |a osteoblast | ||
| 653 | |a osteoblasts | ||
| 653 | |a osteoclast | ||
| 653 | |a osteoclastogenesis | ||
| 653 | |a parathyroid hormone | ||
| 653 | |a pathology | ||
| 653 | |a progenitor cells | ||
| 653 | |a proliferation | ||
| 653 | |a rat | ||
| 653 | |a receptor activator of nuclear factor ?B | ||
| 653 | |a rheumatoid arthritis | ||
| 653 | |a rheumatoid factor | ||
| 653 | |a sclareol | ||
| 653 | |a shared epitope | ||
| 653 | |a SMA- and MAD-related protein | ||
| 653 | |a small-molecule inhibitor | ||
| 653 | |a SOX9 | ||
| 653 | |a spinal fusion | ||
| 653 | |a spondyloarthropathies | ||
| 653 | |a stem cell | ||
| 653 | |a structure | ||
| 653 | |a synovial cell | ||
| 653 | |a Th17 | ||
| 653 | |a Th9 lymphocytes | ||
| 653 | |a therapeutic antibody | ||
| 653 | |a therapeutics | ||
| 653 | |a therapy | ||
| 653 | |a TNF-? | ||
| 653 | |a TNF? | ||
| 653 | |a Traditional Chinese medicine | ||
| 653 | |a transforming growth factor ? | ||
| 653 | |a tripterine | ||
| 653 | |a triptolide | ||
| 653 | |a triterpenoid | ||
| 653 | |a tumor necrosis factor-alpha | ||
| 653 | |a visfatin | ||
| 653 | |a WNT | ||
| 793 | 0 | |a DOAB Library. | |
| 856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/58295 |7 0 |z Open Access: DOAB: description of the publication |
| 856 | 4 | 0 | |u https://mdpi.com/books/pdfview/book/1327 |7 0 |z Open Access: DOAB, download the publication |